Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging
September 18, 2024 11:07 ET
|
Io Therapeutics, Inc.
Io Therapeutics, Inc., presented on IRX4204 for treatment of brain aging, at the FASEB Conference on Cellular and Molecular Mechanisms of Brain Aging
Triamcinolone Market to Reach $1.3 Billion, Globally, by 2033 at 3.8% CAGR: Allied Market Research
September 18, 2024 06:28 ET
|
Allied Analytics LLP
Wilmington, Delaware, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Triamcinolone Market by Type (Cream, Injection and Inhalers), Application (Eczema,...
Deuxième cérémonie annuelle de MADD Canada en hommage aux victimes ontariennes de la conduite avec capacités affaiblies
September 14, 2024 07:00 ET
|
MADD Canada
BRAMPTON, Ontario, 14 sept. 2024 (GLOBE NEWSWIRE) -- Les familles et les amis des victimes tuées dans des collisions dues à l’alcool, au cannabis et/ou à d’autres drogues se rassembleront...
MADD Canada Holds Second Annual Ceremony for Ontario Victims of Impaired Driving
September 14, 2024 07:00 ET
|
MADD Canada
BRAMPTON, Ontario, Sept. 14, 2024 (GLOBE NEWSWIRE) -- Families and friends whose loved ones have been killed in alcohol, cannabis and/or other drug-related crashes will gather today for the second...
Osteal Therapeutics Presents Positive Six-Month Results from the APEX Clinical Trial Program at the 34th Annual Musculoskeletal Infection Society Meeting
August 05, 2024 12:28 ET
|
Osteal Therapeutics
DALLAS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination drug/device therapies for...
Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
July 25, 2024 05:00 ET
|
Kaerus Bioscience
LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of...
[Latest] Global Glycomics Market Size/Share Worth USD 5.2 Billion by 2033 at a 13.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
July 05, 2024 03:30 ET
|
Custom Market Insights
Austin, TX, USA, July 05, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Glycomics Market Size, Trends and Insights By Product Type (Reagents, Enzymes,...
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
July 02, 2024 16:05 ET
|
Avid Bioservices, Inc
-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million -- -- New Mammalian and Cell and...
Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate
June 05, 2024 09:00 ET
|
Osteal Therapeutics
Osteal Therapeutics secured $50M in Series D financing led by Zimmer Biomet. The funds will advance VT-X7, a treatment for periprosthetic joint infection.
Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance
May 23, 2024 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...